Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Teva
Accenture
Express Scripts
AstraZeneca
Queensland Health
Boehringer Ingelheim
Healthtrust
Colorcon

Generated: June 19, 2018

DrugPatentWatch Database Preview

RESCRIPTOR Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Rescriptor, and when can generic versions of Rescriptor launch?

Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty countries.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. One supplier is listed for this compound. Additional details are available on the delavirdine mesylate profile page.
Summary for RESCRIPTOR
Drug patent expirations by year for RESCRIPTOR
Medical Subject Heading (MeSH) Categories for RESCRIPTOR
Synonyms for RESCRIPTOR
(1-(5-METHANSULPHONAMIDO-1H-INDOL-2-YL-CARBONYL)4-[METHYLAMINO)PYRIDINYL]PIPERAZINE
(N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide)
1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine
1-(5-Methanesulphonamido)-1H-indol-2-yl-carbonyl)-4-[3-(isopropylamino)-2-pyridinyl]piperaz
136817-59-9
147221-93-0 (mesylate)
2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
AB01275468-01
AC1L1KRN
AK129758
AKOS015965076
AN-566
API0000513
AX8123689
BC219340
BDBM1944
BHAP der
BHAP-U 90152
C-22553
C06941
C22H28N6O3S
CAS-136817-59-9
CC-26317
CHEBI:119573
CHEMBL593
CS-1660
CTK8E7248
D07782
D0G6SD
DB00705
Delavirdin
Delavirdina
Delavirdine
Delavirdine (*Mesylate salt*)
Delavirdine (INN)
Delavirdine [INN]
Delavirdine(U-90152) & .a.IFN
Delavirdinum
DLV
DOL5F9JD3E
DR002824
DSSTox_CID_2892
DSSTox_GSID_22892
DSSTox_RID_76776
DTXSID6022892
FT-0603115
HE308341
HMS2089F20
HY-10571
J-006916
KB-49645
KB-78327
LS-172972
MET046
Methanesulfonamide, N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-
Methanesulfonamide,N-[2-[[4-[3-[(1-methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]-
MolPort-003-846-188
N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide
N-(2-(4-(3-(Isopropylamino)pyridin-2-yl)piperazine-1-carbonyl)-1H-indol-5-yl)methanesulfonamide
N-(2-{4-[3-(isopropylamino)pyridin-2-yl]piperazine-1-carbonyl}-1H-indol-5-yl)methanesulfonamide
N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide
N-[2-(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazine-1-carbonyl)-1H-indol-5-yl]methanesulfonamide
N-[2-[4-[3-(isopropylamino)-2-pyridyl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide
N-{2-[(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide
N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide
NCGC00168776-01
NCGC00168776-02
NCGC00168776-03
Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- & alpha-Interferon
Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-& alpha-Interferon
PNU-90152-T
Rescriptor (TM)
Rescriptor (TN)
RT-012247
SC-82579
SCHEMBL34420
SPP
Tox21_112637
Tox21_112637_1
U 90152
u-90152
U90152S (*Mesylate salt*)
UNII-DOL5F9JD3E
ZINC18516586

US Patents and Regulatory Information for RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 ➤ Sign Up ➤ Sign Up
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for RESCRIPTOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,108,864 Tablet formation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Moodys
Cipla
Farmers Insurance
Express Scripts
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.